Market cap
$2,371 Mln
Revenue (TTM)
$1,959 Mln
P/E Ratio
15.9
P/B Ratio
2.7
Div. Yield
0 %
| Mednax Inc (MD) | Encompass Health Corp (EHC) | The Ensign Group (ENSG) | Chemed Corp (CHE) | NeoGenomics (NEO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
2,371 | 13,359 | 10,590 | 6,930 | 2,249 |
Revenue ($ Mln) |
1,959 | 6,338 | 5,674 | 2,661 | 788 |
Net Profit ($ Mln) |
150.09 | 644.40 | 399.12 | 282.40 | -32.30 |
Net Margin (%) |
7.66 | 10.17 | 7.03 | 10.61 | -4.10 |
RoE (%) |
17.37 | 18.46 | 16.19 | 33.04 | -3.96 |
Price to Earnings |
15.95 | 21.74 | 27.01 | 25.61 | -- |
Price-To-Book |
2.67 | 4.82 | 4.25 | 8.04 | 2.81 |
Income Statement ($ Mln)
| Mednax Inc (MD) | Encompass Health Corp (EHC) | The Ensign Group (ENSG) | Chemed Corp (CHE) | NeoGenomics (NEO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,959.12 | 6,338.10 | 5,674.31 | 2,661.04 | 787.75 |
|
Cost of Revenue
|
1,453.07 | 3,896.00 | 4,838.38 | 1,818.79 | 442.71 |
|
Gross Profit
|
471.88 | 2,564.90 | 799.45 | 758.34 | 282.54 |
|
Operating Expenses
|
282.68 | 1,280.70 | 326.77 | 471.57 | 392.14 |
|
Operating Profit (EBIT)
|
223.38 | 1,161.40 | 509.16 | 370.86 | -47.09 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
203.43 | 1,065.80 | 532.53 | 382.32 | -36.18 |
|
Provision for Tax
|
53.34 | 218.80 | 133.02 | 99.92 | -3.88 |
|
Profit after Tax (Net Income)
|
150.09 | 644.40 | 399.12 | 282.40 | -32.30 |
|
Minority Interest
|
0.00 | -164.20 | -0.39 | 0.00 | 0.00 |
|
Consolidated Profit
|
33.68 | 145.70 | 0.00 | 76.75 | 0.00 |
Liabilities ($ Mln)
| Mednax Inc (MD) | Encompass Health Corp (EHC) | The Ensign Group (ENSG) | Chemed Corp (CHE) | NeoGenomics (NEO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
849.62 | 2,681.20 | 2,559.31 | 861.42 | 800.64 |
|
Minority Interest
|
0.00 | -164.20 | -0.39 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
754.07 | 3,077.90 | 2,472.09 | 526.08 | 460.11 |
|
Current Liabilities
|
535.73 | 927.40 | 962.91 | 330.93 | 116.17 |
|
Total Liabilities
|
2,246.70 | 7,089.70 | 5,462.97 | 1,640.01 | 1,359.83 |
Assets ($ Mln)
| Mednax Inc (MD) | Encompass Health Corp (EHC) | The Ensign Group (ENSG) | Chemed Corp (CHE) | NeoGenomics (NEO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,455.34 | 6,553.50 | 4,843.51 | 1,352.71 | 966.83 |
|
Current Assets
|
684.08 | 1,013.00 | 1,154.88 | 365.73 | 410.08 |
|
Total Assets
|
2,246.70 | 7,089.70 | 5,462.97 | 1,640.01 | 1,359.83 |
|
Total Debt*
|
612.00 | 2,803.40 | 2,287.65 | 392.19 | 449.14 |
|
Net Current Assets
|
148.35 | 0.00 | 191.97 | 0.00 | 293.91 |
Cashflow ($ Mln)
| Mednax Inc (MD) | Encompass Health Corp (EHC) | The Ensign Group (ENSG) | Chemed Corp (CHE) | NeoGenomics (NEO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
271.09 | 1,175.60 | 564.27 | 388.27 | 5.23 |
|
Cash Flow from Investing Activities
|
-18.30 | -762.80 | -513.18 | -59.34 | -12.34 |
|
Cash from Financing Activities
|
-107.49 | -433.00 | -11.81 | -432.77 | -200.29 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Mednax Inc (MD) | Encompass Health Corp (EHC) | The Ensign Group (ENSG) | Chemed Corp (CHE) | NeoGenomics (NEO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
11.20 | 11.40 | 6.75 | 22.16 | -7.67 |
|
ROE (%)
|
17.37 | 18.46 | 16.19 | 33.04 | -3.96 |
|
ROA (%)
|
5.70 | 7.95 | 6.13 | 14.12 | -2.18 |
|
EBIT Margin (%)
|
11.55 | 18.82 | 9.53 | 14.23 | -4.18 |
|
Net Margin (%)
|
7.66 | 10.17 | 7.03 | 10.61 | -4.10 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Mednax Inc (MD) | Encompass Health Corp (EHC) | The Ensign Group (ENSG) | Chemed Corp (CHE) | NeoGenomics (NEO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
1.91 | 9.36 | 17.49 | 5.15 | 11.08 |
|
EBIT Growth (%)
|
-3.82 | 16.63 | 22.99 | 1.29 | 70.01 |
|
Net Profit Growth (%)
|
-7.46 | 19.11 | 21.61 | 1.29 | 71.54 |
|
EPS Growth (%)
|
-2.78 | 21.08 | 20.07 | 10.23 | 71.79 |
|
Book Value Growth (%)
|
2.43 | 15.90 | 20.05 | -11.47 | -4.99 |
Valuation Ratios
| Mednax Inc (MD) | Encompass Health Corp (EHC) | The Ensign Group (ENSG) | Chemed Corp (CHE) | NeoGenomics (NEO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
10.92 | 19.12 | 30.03 | 22.57 | -14.01 |
|
Price / Book Value
|
2.09 | 4.44 | 4.63 | 6.11 | 1.81 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
7.17 | 9.54 | 24.49 | 14.37 | -47.18 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Mednax Inc (MD) | Encompass Health Corp (EHC) | The Ensign Group (ENSG) | Chemed Corp (CHE) | NeoGenomics (NEO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.47 | 0.00 | 0.08 | 0.00 | 0.47 |
|
Short term debt to equity ratio
|
0.22 | 0.03 | 0.05 | 0.05 | 0.01 |
|
Current Ratio
|
1.28 | 1.09 | 1.20 | 1.11 | 3.53 |
|
Quick Ratio
|
1.28 | 1.09 | 1.20 | 1.08 | 3.31 |
|
Interest Coverage
|
7.11 | 9.39 | 66.70 | 78.72 | -10.15 |
Operating Efficiency Ratios
| Mednax Inc (MD) | Encompass Health Corp (EHC) | The Ensign Group (ENSG) | Chemed Corp (CHE) | NeoGenomics (NEO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
12.27 | 11.23 | 11.72 | 9.58 | 27.09 |
|
Asset Turnover
|
0.74 | 0.78 | 0.87 | 1.33 | 0.53 |
|
Receivable days
|
49.13 | 37.48 | 43.58 | 25.53 | 77.78 |
|
Inventory Days
|
-- | -- | -- | 1.62 | 22.71 |
|
Payable days
|
10.59 | 18.92 | 8.42 | 10.06 | 18.35 |
|
Cash Conversion Cycle
|
-- | -- | -- | 17.10 | 82.14 |